[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-vein-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-vein-occlusion":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,78,99,133,160,201,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":4,"leadSponsor":46,"locationsCount":49},"100170772","national-eye-institute-biorepository-for-retinal-diseases-100170772",false,"NCT01496625","National Eye Institute Biorepository for Retinal Diseases","NEI Intramural Biorepository for Retinal Diseases","* INCLUSION CRITERIA:\n\nParticipants will be eligible if they:\n\n* Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children.\n* Manifest diagnosed or undiagnosed retinal disease(s), or could serve as an unaffected control suitable for comparison to participants with various retinal diseases, particularly AMD and diabetic retinopathy (taking into account matching factors such as age and past ocular history).\n\nEXCLUSION CRITERIA:\n\nParticipants will not be eligible if they:\n\n* Are unable or unwilling to give informed consent that includes collection and study of at least one peripheral blood sample.\n* Are unable or unwilling to give informed consent that includes use of NIH medical records and clinical samples for research.\n* Have a systemic disease that compromises the ability to provide adequate ophthalmologic examination or treatment.",true,"ALL","2 Years","120 Years",{"count":21,"type":22},650,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes, cells, and tissues may help them understand why some people get eye problems and others do not, or why some people respond to treatment while others do not. Researchers want to collect physical samples and personal data to develop a National Eye Institute database.\n\nObjectives:\n\n\\- To collect health information and blood and tissue samples from people with and without eye diseases, to be used in research studies.\n\nEligibility:\n\n* Individuals at least 2 years of age with different types of eye disease.\n* Healthy volunteers with no history of eye disease.\n\nDesign:\n\n* Participants may be recruited from National Eye Institute studies or may be referred from other sources.\n* Participants will be screened with a physical exam and medical history. They will also have a full eye exam. Questions will be asked about family medical history, especially about eye disease.\n* Blood samples will be collected. Other samples, such as saliva, tears, hair, stool, and urine, may be collected as needed. Adult participants may also provide a skin sample.\n* Tissue or fluid from eye collected as part of eye care or treatment may also be added to the database.\n* No treatment will be provided as part of this study.",[26,27,28,29,30],"Age-Related Macular Degeneration","Diabetic Retinopathy","Von Hippel-Lindau Syndrome","Retinal Disease","Retinal Vein Occlusion",[32,29,27,33,34,35,36,37,38],"Biological Specimens","Phenotype-Genotype correlation","Age-Related Macular Degeneration (AMD)","Natural History","AMD","Healthy Volunteer","HV","RECRUITING","2026-06-27",{"date":42,"type":43},"2026-06-30","ACTUAL",{"date":45,"type":43},"2012-06-18",{"name":47,"class":48},"National Eye Institute (NEI)","NIH",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100401313","optical-coherence-tomography-angiography-in-subjects-with-retinal-vascular-disease-100401313","NCT04505618","Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease","OCTA-RVD","Exclusion Criteria:\n\n* Both subjects with diseases and controls:\n* Children (age\\\u003C18)\n* Pregnant females\n* Developmentally delayed subjects\n* Subjects unable to provide informed consent\n* Inability to cooperate with tests and study instructions\n* Images with motion artifact or signal strength \\\u003C 7\n* History of glaucoma\n* History of age-related macular degeneration\n* History of any visually significant eye disease\n* History of proliferative diabetic retinopathy\n* History of any inflammatory disease\n* History of heart disease\n* History of thyroid disease.\n* Additional criteria for controls:\n* History of any type of Diabetes Mellitus\n* History of any type of Hypertension","18 Years","99 Years",{"count":60,"type":22},1050,"INTERVENTIONAL",[63],"NA","This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.",[27,30,66,67],"Hypertension,Essential","Retinal Vascular Disorder","2026-06-15",{"date":70,"type":43},"2026-06-17",{"date":72,"type":43},"2019-10-01",{"date":74,"type":22},"2027-09-01",{"name":76,"class":77},"Johns Hopkins University","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":61,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":49},"100338003","soluble-cluster-of-differentiation-160-scd160-in-sera-and-intra-ocular-fluids-association-with-ischaemic-retinopathies-100338003","NCT03680794","Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies","sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies","inclusion criteria :\n\n* over 18 years old\n* with social security affiliation\n* willing to participate this study non-inclusion criteria :\n* any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids, or immunosuppressive agents\n* any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation\n* any serious allergy to the fluorescein sodium for injection in angiography\n* any history of previous systemic anti-VEGF treatment\n* any history of inflammatory or auto-immune disease\n* any active extraocular inflammation or infection in the last 4 weeks before surgery exclusion criteria :\n* Patients with C-reactive protein CRP \\> 10mg\u002FmL (serum sampling during surgery)",{"count":86,"type":22},120,[63],"CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF\u002FVEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test.\n\nThe investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.",[27,30],"2026-04-27",{"date":92,"type":43},"2026-04-30",{"date":94,"type":43},"2018-06-27",{"date":96,"type":22},"2028-02-27",{"name":98,"class":77},"CHU de Reims",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":61,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100629963","speculum-free-intravitreal-injection-using-cotton-tipped-applicator-retraction-a-randomized-trial-of-pain-procedure-time-patient-satisfaction-and-safety-100629963","NCT07481500","Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Controlled Trial Comparing Pain Perception, Procedure Duration, Patient Satisfaction, and Safety Between Eyelid Speculum and Cotton-Tipped Applicator Retraction Techniques","IVI-RETRACT","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Diagnosed with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or retinal vein occlusion (RVO)\n3. Scheduled for intravitreal anti-VEGF injection (bevacizumab, aflibercept, or faricimab)\n4. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Active ocular infection or inflammation\n2. Known allergy to povidone-iodine, tetracaine, or levofloxacin\n3. Inability to cooperate with the injection procedure\n4. Concurrent participation in another interventional clinical trial\n5. Anatomical eyelid abnormality precluding use of either retraction technique",{"count":86,"type":22},[63],"This randomized controlled trial compares two techniques for eyelid retraction during intravitreal injection (IVI) of anti-VEGF agents: the standard wire eyelid speculum (Group A) versus cotton-tipped applicator retraction (Group B) in patients with neovascular AMD, diabetic macular edema, or retinal vein occlusion.\n\nThe study evaluates four outcomes: (1) patient pain perception measured by a 10-cm visual analogue scale immediately after injection; (2) procedure duration from retraction device placement to removal; (3) patient satisfaction assessed by a 5-item Likert scale; and (4) safety including rates of subconjunctival hemorrhage, corneal abrasion, endophthalmitis, and intraocular pressure elevation.\n\nA novel syringe cap technique using the Terumo 31G insulin syringe plastic cap as an injection-site marker (3.5 mm for pseudophakic eyes, 5.0 mm for phakic eyes from the limbus) is employed in both groups, replacing the traditional caliper.\n\nRandomization is stratified by diagnosis and prior injection history using permuted block randomization (block sizes 4 and 6). The target sample size is 120 patients (60 per group) at Walailak University Hospital, Nakhon Si Thammarat, Thailand.",[111,112,30,113],"Neovascular Age-Related Macular Degeneration (nAMD)","Diabetic Macular Edema","Intravitreal Injections",[115,116,117,118,119,120,121,122],"intravitreal injection","eyelid speculum","cotton-tipped applicator","injection pain","procedure time","patient satisfaction","anti-VEGF","randomized controlled trial","NOT_YET_RECRUITING","2026-03-13",{"date":126,"type":43},"2026-03-18",{"date":128,"type":22},"2026-06",{"date":130,"type":22},"2027-08",{"name":132,"class":77},"Jakkrit Juhong",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":61,"phases":142,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":49},"100363123","early-phase-1-feasibility-and-safety-of-mb-102-in-ocular-angiography-as-compared-to-fluorescein-sodium-100363123","NCT04008121","Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium","A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium","Inclusion Criteria:\n\n* Age \\> 18 years - male or female\n\n  1. Eligible female non-pregnant participants who are either not of child-bearing potential or willing to utilize adequate contraception during the trial\n  2. Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose\n* Participants willing to comply with study requirements\n* Participants who have signed an informed consent form\n\nAt least 5 participants will have a current history of retinal or choroidal vascular diseases.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to utilize adequate contraception\n* Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study\n* History of drug or alcohol abuse within the past year\n* History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy).\n* Prior history of seizures\n* Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs\n* Site personnel immediately associated with the study or their immediate family members\n* Unable to tolerate ophthalmologic imaging\n* Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial (e.g. unstable medical condition including cardiovascular disease, or other conditions considered clinically significant or unstable by the Principal Investigator)\n* Prior enrollment and dosing in this study",{"count":141,"type":22},10,[143],"EARLY_PHASE1","The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.",[146,30,27,147],"Retinopathy","Macular Degeneration",[149],"Fluorescein angiography","2026-02-02",{"date":152,"type":43},"2026-02-04",{"date":154,"type":43},"2025-11-06",{"date":156,"type":22},"2026-12",{"name":158,"class":159},"MediBeacon","INDUSTRY",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":170,"conditions":171,"keywords":185,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100615866","wide-field-octa-in-ocular-diseases-100615866","NCT07298174","Wide Field OCTA in Ocular Diseases","Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.","WOOD-2025","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both genders\n* Confirmed diagnosis of one of the above diseases\n* Age-related macular degeneration\n* Diabetic retinopathy\n* Myopia\n* Pachychoroid spectrum disease\n* Inherited retinal dystrophy\n* Uveitis\n* Dry eye\n* Visual acuity of at least 1\u002F20\n* Signed informed consent for the participation to the trial.\n\nExclusion Criteria:\n\n* Media opacities\n* Any other eye or systemic condition that may irreversibly impair the results of the study\n* Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment",{"count":169,"type":22},200,"The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.\n\nOn the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.\n\nThe main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.",[172,112,27,173,174,175,176,177,178,179,180,181,182,183,184,30],"Age - Related Macular Degeneration (AMD)","Myopia","Inherited Retinal Disease","Stargardt Disease","Retinitis Pigmentosa (RP)","Best Disease","Geographic Atrophy","Macular Neovascularisation","Ocular Surface Disease","Central Serous Choroidopathy","Pachychoroid Disease","Uveitis","Vitreoretinal Disease",[186,187,188,189,190,191],"wide-field octa","multimodal retinal imaging","quantitative imaging","retinal disease","macular disease","ocular surface disease","2025-12-22",{"date":194,"type":43},"2025-12-30",{"date":196,"type":22},"2026-01",{"date":198,"type":22},"2028-05",{"name":200,"class":77},"IRCCS San Raffaele",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":61,"phases":211,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":49},"100612926","phase-2-safety-and-proof-of-concept-study-of-anxv-annexin-a5-in-patients-with-diabetic-retinopathy-or-retinal-vein-occlusion-100612926","NCT07259928","Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion","Open-label, Safety, Tolerability and Proof of Concept Study to Evaluate the Use of ANXV (Recombinant Human Annexin A5 Protein) in the Treatment of Patients With Either Diabetic Retinopathy or Recent Onset Retinal Vein Occlusion","NEXUS","Inclusion Criteria:\n\nTo be eligible to participate in this trial, an individual must meet all the following criteria:\n\n1. Must have given written informed consent (signed and dated), and any authorizations required by local law and be able to comply with all study requirements\n2. Male or female, ≥18 years of age at the time of informed consent\n3. Females should have no childbearing potential according to Clinical Trial Facilitation Group (CTFG) definition.\n4. Clear ocular media and adequate pupillary dilation in the Study Eye to permit high quality retinal imaging\n5. Willing to refrain from unusually strenuous exercise\u002Factivity (for example heavy lifting, weight training, intense aerobics classes etc.) for at least 72 hours prior to study visits\n\n   Additionally, NPDR participants must meet the following criteria to be eligible:\n6. Diagnosed with moderately severe or severe non-proliferative Diabetic Retinopathy defined as having a DRSS score of 47 and 53 respectively, and no CI-DMO\n7. Found to have an ETDRS BCVA score in the study eye (SE) of ≥69 ETDRS (equivalent to Snellen 6\u002F12 or 20\u002F40)\n\n   Additionally, RVO participants must meet the following criteria to be eligible:\n8. Diagnosed with Retinal Vein Occlusion with onset of symptoms within 28 days prior to first administration of ANXV\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this trial:\n\nGeneral:\n\n1. Unwillingness or inability to attend all study visits and\u002For perform all procedures\u002Ftests\u002Fexaminations, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator\n2. Any major medical or surgical procedure or trauma within 4 weeks prior to the day of trial intervention Treatment 1 (ANXV administration), or planned major surgery within the duration of the study through Day 120\n3. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study\n4. Prior exposure to a recombinant Annexin A5 protein\n5. History of severe allergy\u002Fhypersensitivity or ongoing allergy\u002Fhypersensitivity, as judged by the Investigator, or history of hypersensitivity to biologics (for example systemically administered recombinant proteins\u002Fpeptides; a similar drug class to ANXV)\n6. Uncontrolled hypertension (systolic \\> 180 mmHg or diastolic \\> 110 mmHg)\n7. Current use of any systemically administered anti-angiogenic agent (e.g., bevacizumab, sunitinib, cetuximab, sorafenib, pazopanib) or corticosteroids\n8. Diagnosed untreated systemic metastasis malignancy\n9. A current systemic infection or inflammation that may require antiviral or antimicrobial therapy that will not be completed prior to Screening Visit, or that in the opinion of the Investigator and with concurrence of the Medical Monitor may either put the participant at risk or may influence the results of the study, or the participant's ability to participate in the study\n10. Treatment with another investigational drug, biological agent, or device within 3 months of Screening Visit, or 5 half-lives of investigational agent, whichever is longer or planned participation in an interventional trial from signing Informed Consent Form (ICF) through Day 120\n11. History of thromboembolic events or deep venous thrombosis within 3 months of Screening Visit\n12. Current use of anticoagulant medication (any medications that might have effect on coagulation, haemostasis, and platelets); low dose aspirin allowed prior to informed consent but must be stopped at the time of consent; may begin again 1 day post Treatment 5 infusion\n13. Current daily use of benzodiazepines\n14. Clinically significant abnormal coagulation parameters at baseline\n15. History of autoimmune disease with anticipated presence of persistent Annexin A5 antibodies, e.g., antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, Behcet disease or systemic sclerosis\n16. Inherited blood disorder (e.g. sickle cell disease, thalassemia)\n17. History of unstable coronary artery disease or cerebrovascular accident within the last 3 months\n18. Current known kidney disease or evidence of kidney disease and eGFR below 60 mL\u002Fmin\u002F1.73m2 at baseline\n19. Current drug or alcohol abuse as per the opinion of the Investigator, or current excessive nicotine intake (e.g. ≥ 20 cigarettes\u002Fday, or equivalent, as per the opinion of the Investigator)\n20. Known history of or positive test for chronic infection that affect the immune system (e.g. hepatitis C (HCV), chronic hepatitis B (HBV) and HIV)\n21. Class III obesity (Body Mass Index ≥ 40kg\u002Fm2), at the time of informed consent\n22. Within 6 months prior to the Screening Visit, use of medications known to be toxic to the retina, lens, or optic nerve (e.g., deferoxamine, chloroquine\u002Fhydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, and ethambutol)\n23. Known hypersensitivity or allergy to fluorescein (e.g., bronchospasm, rash, etc.) or to any component of the study products or a contraindication to dilation of the pupil or fixed pupils; mild allergies without angio-oedema or treatment need may be acceptable if deemed not to be of clinical significance (including but not limited to allergy to animals or mild seasonal hay fever)\n\n    Either or both eyes:\n24. A severe (≥0.9 log, Grade 3+ or worse) Relative Afferent Pupillary Defect (RAPD)\n25. An IOP greater than 24 mmHg that is not controlled with medication or surgery at the time of the Screening Visit\n26. Recent (6 months) history of, or presence of uveitis, presence of intraocular inflammation (history of blepharitis is not exclusionary), current ocular infection\n27. Evidence of neovascularization\n28. ETDRS BCVA score in the Fellow eye of ≤54 (equivalent to Snellen 6\u002F24 or 20\u002F80)\n29. Ocular disorders\u002Fadditional eye disease, which in the opinion of the Investigator may confound interpretation of study results, compromise protocol assessments or are likely to require intervention during the study, including, but not limited to, atrophy of the retinal pigment epithelium, sub-retinal fibrosis, organized hard exudate plaque, retinal detachment, macular hole, vitreomacular traction, macular epiretinal membrane, clinically significant cataract, vitreous opacities or haemorrhage, glaucoma with documented visual field loss, ischemic optic neuropathy, retinitis pigmentosa or choroidal neovascularization of any cause (e.g., AMD, ocular histoplasmosis, toxoplasmosis, or pathologic myopia)\n30. Receipt within the past 6 months or ongoing intravitreal injection of anti-VEGF treatment in either eye\n\n    Study Eye only:\n31. Evidence of deep intraretinal haemorrhage involving the centre 1mm of the macula\n32. Laser photocoagulation in the study eye within the preceding 6 months prior to the Screening Visit, or likely to receive during the study period\n33. Intraocular surgery (including refractive surgery, cataract surgery), or intravitreal (IVT) injection within the preceding 6 months prior to the Screening Visit, or cataract surgery within the preceding 3 months prior to the Screening Visit, or planned intraocular surgery or procedure during the study\n34. Recent (6 months) history, or current evidence of ocular herpetic diseases (including herpes simplex virus, varicella zoster or cytomegalovirus)\n\n    NPDR participants will not be eligible if they meet any of the following criteria (only NPDR participants):\n35. CI-DMO in either eye which, in the opinion of the Investigator, qualifies for anti-VEGF or laser treatment",{"count":210,"type":22},12,[212],"PHASE2","The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in adults. The main questions it aims to answer are:\n\n* Is ANXV safe to use?\n* Does ANXV improve vision or findings related to vision decrease caused by non-proliferative diabetic retinopathy or retinal vein occlusion?\n* Does ANXV lower the number of times participants need to use a rescue medication? Researchers will compare different dose levels of ANXV to see what dose would be be appropriate to test in larger studies.\n\nParticipants will:\n\nTake ANXV as a 30 minutes infusion (slow injection) for 5 days. Visit the clinic for checkups and tests at 11 visits during 4 months.",[215,30],"Non-Proliferative Diabetic Retinopathy",[217,218,30,219,220,221],"Annexin A5","ANXV","Non-Profilerative Diabetic Retinopathy","RVO","NPDR","2025-11-28",{"date":224,"type":43},"2025-12-02",{"date":226,"type":43},"2025-11-07",{"date":228,"type":22},"2026-07",{"name":230,"class":159},"Annexin Pharmaceuticals AB",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":61,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":49},"100593125","effect-of-video-viewing-on-intravitreal-injection-experience-100593125","NCT07002372","Effect of Video Viewing on Intravitreal Injection Experience","Impact of Procedural Video Viewing on Patients Undergoing Intravitreal Anti-VEGF Injections","Inclusion Criteria:\n\n* Patients who are receiving their first intravitreal injection of anti-VEGF medication due to retinal diseases\n* Mentally competent, and able to communicate without barriers\n* Willing to voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* History of previous eye surgery\n* Best-corrected visual acuity in the better eye worse than 0.3\n* The target eye is complicated with neovascular glaucoma.",{"count":239,"type":22},182,[63],"Study Objective The goal of this clinical trial is to evaluate whether viewing a procedural video can improve the patient experience and reduce the incidence and severity of subconjunctival hemorrhage in individuals undergoing intravitreal anti-VEGF injections.\n\nKey Research Questions\n\n1. Can viewing the procedural video prior to treatment reduce the rate and\u002For area of subconjunctival hemorrhage?\n2. Can the video improve the patient experience, specifically by reducing anxiety levels and increasing satisfaction with the treatment process?\n\nStudy Design Participants will be randomly assigned to either an intervention group, who will watch an educational video explaining the injection procedure, or a control group, who will not view the video.\n\nAll participants will complete the State-Trait Anxiety Inventory-State (STAI-S) questionnaire both before and after treatment to assess changes in anxiety levels.",[243,27,244,30,245],"Age Related Macular Degeneration","Choroidal Neovascularization","Cystoid Macular Edema","2025-06-01",{"date":248,"type":43},"2025-06-03",{"date":250,"type":43},"2025-05-05",{"date":252,"type":22},"2025-10-05",{"name":254,"class":77},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]